UCL Discovery Stage
UCL home » Library Services » Electronic resources » UCL Discovery Stage

NFL and CXCL13 may reveal disease activity in clinically and radiologically stable MS

Novakova, L; Axelsson, M; Malmeström, C; Zetterberg, H; Blennow, K; Svenningsson, A; Lycke, J; (2020) NFL and CXCL13 may reveal disease activity in clinically and radiologically stable MS. Multiple Sclerosis and Related Disorders , 46 , Article 102463. 10.1016/j.msard.2020.102463. Green open access

[thumbnail of Zetterberg_Novakova.pdf]
Preview
Text
Zetterberg_Novakova.pdf - Accepted Version

Download (723kB) | Preview

Abstract

BACKGROUND: Cerebrospinal fluid (CSF) levels of neurofilament light (NFL), a biomarker of axonal damage, and CXCL13, a chemokine involved in B-cell regulation, are both associated with disease activity in multiple sclerosis (MS). OBJECTIVE: To explore the potential of NFL and CXCL13 to detect residual disease activity in patients with no signs of clinical or ongoing radiological activity and to study the clinical relevance of such activity. METHODS: NFL and CXCL13 concentrations were determined with ELISA in CSF obtained from 90 relapsing-remitting (RR) MS and 47 Progressive (Pr) MS (including primary and secondary PrMS) at baseline and after 12 months of follow-up. The patients were assessed at baseline, before initiating or switching disease modifying therapy (DMT) and again after 12 and 27 months of follow-up. RESULTS: All patients with ongoing disease activity (relapse or contrast-enhancing lesions on MRI) had increased NFL or CXCL13. The proportion of RRMS and PrMS patients without ongoing disease activity with elevation of either NFL or CXCL13 (residual disease activity) was 39% and 50%, respectively, and both were increased in 11% and 16%, respectively. The treatment with DMTs decreased the proportion with residual disease activity in both RRMS and PrMS significantly. We could not show any significant association between residual disease activity and clinical or MRI measures at 12 or 27 months of follow-up. CONCLUSIONS: Although most of this real-world study population had been treated with second-line DMTs and achieved clinical and radiological stability, a significant proportion of patients still displayed increased CSF levels of both NFL and CXCL13, indicating residual disease activity. Thus, these markers seemed considerably more sensitive to disease activity than clinical and MRI measures. However, the long-term clinical significance of such activity remains to be determined.

Type: Article
Title: NFL and CXCL13 may reveal disease activity in clinically and radiologically stable MS
Location: Netherlands
Open access status: An open access version is available from UCL Discovery
DOI: 10.1016/j.msard.2020.102463
Publisher version: https://doi.org/10.1016/j.msard.2020.102463
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: Biomarker, CXCL13, Cerebrospinal fluid, Disease activity, Multiple sclerosis, Neurofilament light
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neurodegenerative Diseases
URI: https://discovery-pp.ucl.ac.uk/id/eprint/10110273
Downloads since deposit
17,404Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item